Advances in the treatment of hepatitis C virus infection

Topics in Antiviral Medicine

Volumn 20, Issue 1, 2012, Pages 5-10

  Thomas, David L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; DRUG DERIVATIVE; N (3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL) 3 (2 ((((1,1 DIMETHYLETHYL)AMINO)CARBONYL)AMINO) 3,3 DIMETHYL 1 OXOBUTYL) 6,6 DIMETHYL 3 AZABICYCLO(3.1.0)HEXAN 2 CARBOXAMIDE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

ARTICLE; DRUG EFFECT; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MORTALITY; UNITED STATES; VIROLOGY;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; RIBAVIRIN; UNITED STATES;

EID: 84862020944     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271-278.
2. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
3. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014-1024.
4. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
5. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417-2428.
6. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-1217.
7. Vierling JM, Kwo PY, Lawitz E, et al. Frequencies of resistance-associated amino acid variants following combination treatment with boceprevir plus PEGINTRON (peginterferon alfa-2b)/ribavirin in patients with chronic hepatitis C (CHC), genotype 1 (G1). Hepatology. 2010;52(Suppl S1):702A-703A.
8. Telaprevir [package insert]. Cambridge, MA: Vertex Pharmaceuticals; 2011.
9. Zeuzem S, Sulkowski M, Zoulim F, et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the Extend study. Hepatology. 2010;52(Suppl S1):436A.
10. Boceprevir [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2011.
11. Sulkowski M, Dieterich D, Sherman K, et al. Interim analysis of a phase 2a doubleblind study of TVR in combination with pegIFN-alfa2a and RBV in HIV/HCV coinfected patients. [Abstract 146LB.] 18th Conference on Retroviruses and Op-portunistic Infections (CROI). February 27-March 2, 2011; Boston, MA.
12. Sulkowski M, Pol S, Cooper C, et al. Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients: interim on-treatment results. [Abstract LB-37.] 49th Annual Meeting of the Infectious Diseases Society of America (IDSA). October 20-23, 2011; Boston, MA.
13. Dieterich D, Soriano V, Sherman K, et al. Telaprevir in combination with pegylated interferon-a-2a+RBV in HCV/HIV-co-infected patients: a 24-week treatment interim analysis. [Abstract 46.] 19th Conference on Retroviruses and Opportunistic Infections (CROI). March 5-8, 2012; Seattle, WA.
14. Sulkowski M, Pol S, Cooper C, et al. Boceprevir + pegylated interferon + ribavirin for the treatment of HCV/HIV-co-infected patients: end of treatment (week-48) interim results. [Abstract 47.] Proceedings from the 19th Conference on Retroviruses and Opportunistic infections (CROI). March 5-8, 2012; Seattle, WA.
15. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216-224.